OriGene Logo
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right

Search Results

Your search returned 9 results.
Search:

SKU Category Vector Description Price Delivery
SC126713 Human cDNA pCMV6-XL4 MAP3K7 (untagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D NM_145333.1 $760 Immediate
RC224678 Human ORF PS100001 MAP3K7 (Myc-DDK-tagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D $610 2-3 weeks
RC224678L1 Human ORF PS100064 Lenti-ORF clone of MAP3K7 (Myc-DDK-tagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D, (10ug) $790 2-3 weeks
RC224678L1V Human ORF PS100064 Lenti ORF particles, MAP3K7 (Myc-DDK-tagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D, 200ul, >10^7 TU/mL $1190 5-6 weeks
RC224678L2 Human ORF PS100071 Lenti-ORF clone of MAP3K7 (mGFP-tagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D, (10ug) $870 2-3 weeks
RC224678L2V Human ORF PS100071 Lenti ORF particles, MAP3K7 (mGFP-tagged)-Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D, 200ul, >10^7 TU/mL $1310 5-6 weeks
RG224678 Human ORF PS100010 MAP3K7 (GFP-tagged) - Human mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant D $670 3-4 weeks
HK211801 qPCR Standard qPCR primer pairs and template standards against Homo sapiens gene MAP3K7 NM_145333 $390 5 - 7 Days
/ UTR pMirTarget 3`UTR clone of mitogen-activated protein kinase kinase kinase 7 (MAP3K7) transcript variant D for miRNA target validation NM_145333.1 $510 3-4 weeks
Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title